A conversation with Vivian Cai ’25, a graduate of the Global Business and Society program, whose startup Sustentra helps ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the ...

With help from UVA’s Licensing & Ventures Group, Roversa Robotics is transforming how kids around the world learn computer ...

The new agent, called Asimov, was developed by Reflection, a small but ambitious startup cofounded by top AI researchers from ...

The good news is that AI is no longer only for the big tech companies. It's now a productivity accelerator for individuals, ...

Shares of Recursion Pharmaceuticals RXRX gained 8.7% on Tuesday and continue to gain today. The uptrend was triggered after ...

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor ...

Rallybio Corp., a New Haven-based biotechnology company developing therapies for rare diseases, said Tuesday it has agreed to ...

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...